Auxilium's Xiaflex shows positive Phase 4 results Auxilium announced interim data from its Phase 4 retreatment study evaluating Xiaflex in adult patients with Dupuytren's contracture and a recurrent contracture with a palpable cord. Xiaflexis a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord, and has been granted Orphan Drug Designation in the U.S. by the FDA. 87% of recurrent contractures of metacarpophalangeal joints were successfully retreated. Patients showed an average 83% improvement in fixed flexion. 85% of recurrent contractures of proximal interphalangeal were successfully retreated. Retreatment with CCH was well tolerated.
Endo upgraded to Overweight from Neutral at Piper Jaffray Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
Auxilium downgraded to Neutral from Buy at Mizuho Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.